single dose of CNCT19

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsed or Refractory Acute Lymphoblastic Leukemia

Drug Information

Target Indication

Relapsed or Refractory Acute Lymphoblastic Leukemia

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CLCS

Cell Source, Inc.

Related Pipeline

Osteoarthritis, Knee

Hematological Malignancies

Cytomegalovirus Infection

Hematological Malignancies

Carcinoma, Hepatocellular